These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 35856987)

  • 1. [Considerations in the transgender population regarding HIV infection, antiretroviral therapy, pre-exposure prophylaxis (PreP) and interaction with gender reaffirmation treatment].
    Zapata-Pizarro A; Muena-Bugueño C; Quiroz-Nilo S; Serri-Venegas M; Usedo-López P
    Rev Chilena Infectol; 2022 Apr; 39(2):149-156. PubMed ID: 35856987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV Antiretroviral Treatment and Pre-exposure Prophylaxis in Transgender Individuals.
    Poteat TC; Radix A
    Drugs; 2020 Jul; 80(10):965-972. PubMed ID: 32451925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preexposure Prophylaxis for Human Immunodeficiency Virus Infection for Men Who Have Sex with Men and Transgender Persons:: What Dermatologists Need to Know.
    Katz KA; Park AJ; Marcus JL
    Dermatol Clin; 2020 Apr; 38(2):233-238. PubMed ID: 32115133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reaching transgender populations in Zambia for HIV prevention and linkage to treatment using community-based service delivery.
    Mwango L; Toeque MG; Lindsay B; Tembo K; Sakala H; Reggee S; Malunga SM; Kabwe M; Kafunda I; Olufunso A; Mwila A; Okuku J; Kancheya N; Nkwemu K; Mumba D; Hachaambwa L; Sheneberger R; Blanco N; Lavoie MC; Stafford KA; Claassen CW
    J Int AIDS Soc; 2022 Oct; 25 Suppl 5(Suppl 5):e25995. PubMed ID: 36225155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implementation of a Test, Treat, and Prevent HIV program among men who have sex with men and transgender women in Thailand, 2015-2016.
    Ongwandee S; Lertpiriyasuwat C; Khawcharoenporn T; Chetchotisak P; Thiansukhon E; Leerattanapetch N; Leungwaranan B; Manopaiboon C; Phoorisri T; Visavakum P; Jetsawang B; Poolsawat M; Nookhai S; Vasanti-Uppapokakorn M; Karuchit S; Kittinunvorakoon C; Mock P; Prybylski D; Sukkul AC; Roels T; Martin M
    PLoS One; 2018; 13(7):e0201171. PubMed ID: 30044867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Awareness, knowledge, and attitudes related to HIV pre-exposure prophylaxis and other prevention strategies among physicians from Brazil and Mexico: cross-sectional web-based survey.
    Vega-Ramirez H; Torres TS; Guillen-Diaz C; Pimenta C; Diaz-Sosa D; Konda KA; da Cunha ARC; Robles-Garcia R; Benedetti M; Hoagland B; Bezerra DRB; Caceres CF; Grinsztejn B; Veloso VG;
    BMC Health Serv Res; 2022 Apr; 22(1):532. PubMed ID: 35459177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-related care for transgender people: A systematic review of studies from around the world.
    Vaitses Fontanari AM; Zanella GI; Feijó M; Churchill S; Rodrigues Lobato MI; Costa AB
    Soc Sci Med; 2019 Jun; 230():280-294. PubMed ID: 31035207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring the Association Between Gender Affirmation and PrEP use Among Transgender Women in New York City.
    Rivera AV; Lopez JM; Braunstein SL
    AIDS Behav; 2023 May; 27(5):1523-1530. PubMed ID: 36574185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial.
    Deutsch MB; Glidden DV; Sevelius J; Keatley J; McMahan V; Guanira J; Kallas EG; Chariyalertsak S; Grant RM;
    Lancet HIV; 2015 Dec; 2(12):e512-9. PubMed ID: 26614965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacology and drug interactions with HIV PrEP in transgender persons receiving gender affirming hormone therapy.
    Yager JL; Anderson PL
    Expert Opin Drug Metab Toxicol; 2020 Jun; 16(6):463-474. PubMed ID: 32250177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mapping Community-Engaged Implementation Strategies with Transgender Scientists, Stakeholders, and Trans-Led Community Organizations.
    Restar A; Minalga BJ; Quilantang MI; Adamson T; Dusic E; van der Merwe LA; Millet G; Rosadiño D; Laguing T; Lett E; Everhart A; Phillips G; Janamnuaysook R; Seekaew P; Baker K; Ashley F; Wickersham J; Wallace SE; Operario D; Gamarel KE
    Curr HIV/AIDS Rep; 2023 Jun; 20(3):160-169. PubMed ID: 37012537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increasing Access to Pre-Exposure Prophylaxis Among Transgender Women and Transfeminine Nonbinary Individuals.
    Klein A; Golub SA
    AIDS Patient Care STDS; 2019 Jun; 33(6):262-269. PubMed ID: 31166785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gender-based violence and engagement in biomedical HIV prevention, care and treatment: a scoping review.
    Leddy AM; Weiss E; Yam E; Pulerwitz J
    BMC Public Health; 2019 Jul; 19(1):897. PubMed ID: 31286914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of HIV Partner Services in the Modern Biomedical HIV Prevention Era: A Network Modeling Study.
    Jenness SM; Le Guillou A; Lyles C; Bernstein KT; Krupinsky K; Enns EA; Sullivan PS; Delaney KP
    Sex Transm Dis; 2022 Dec; 49(12):801-807. PubMed ID: 36194831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low PrEP adherence despite high retention among transgender women in Brazil: the PrEParadas study.
    Jalil EM; Torres TS; Luz PM; Monteiro L; Moreira RI; de Castro CRV; Leite IDC; Cunha M; de Cássia Elias Estrela R; Ramos M; Hoagland B; Wagner Cardoso S; Anderson P; Veloso VG; Wilson E; Grinsztejn B;
    J Int AIDS Soc; 2022 Mar; 25(3):e25896. PubMed ID: 35255199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-exposure HIV prophylaxis (PrEP) among transgender women: 3 years of follow-up in a university hospital in Paris.
    Isernia V; Phung B; Lepretre AM; Azadi B; Rincon G; Zelie J; Le Gac S; Deprez A; Michard F; Yazdanpanah Y; Ghosn J
    Sex Transm Infect; 2021 Sep; 97(6):465-466. PubMed ID: 32879028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. "Some of us, we don't know where we're going to be tomorrow." Contextual factors affecting PrEP use and adherence among a diverse sample of transgender women in San Francisco.
    Cahill SR; Keatley J; Wade Taylor S; Sevelius J; Elsesser SA; Geffen SR; Wang T; Mayer KH
    AIDS Care; 2020 May; 32(5):585-593. PubMed ID: 31482726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early antiretroviral therapy and daily pre-exposure prophylaxis for HIV prevention among female sex workers in Cotonou, Benin: a prospective observational demonstration study.
    Mboup A; Béhanzin L; Guédou FA; Geraldo N; Goma-Matsétsé E; Giguère K; Aza-Gnandji M; Kessou L; Diallo M; Kêkê RK; Bachabi M; Dramane K; Geidelberg L; Cianci F; Lafrance C; Affolabi D; Diabaté S; Gagnon MP; Zannou DM; Gangbo F; Boily MC; Vickerman P; Alary M
    J Int AIDS Soc; 2018 Nov; 21(11):e25208. PubMed ID: 31291057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-Exposure Prophylaxis in Trans Populations: Providing Gender-Affirming Prevention for Trans People at High Risk of Acquiring HIV.
    Deutsch MB
    LGBT Health; 2018 Oct; 5(7):387-390. PubMed ID: 30272493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Method of Calculating Renal Function Estimates Could Inappropriately Exclude Transgender Patients Receiving Gender-Affirming Hormone Therapy from Pre-Exposure Prophylaxis Eligibility.
    Patel N; Blumenthal J; Dubé MP; Hood A; Bolan R; Morris S
    LGBT Health; 2022 Apr; 9(3):199-206. PubMed ID: 35196473
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.